[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568241":3},{"organization":4,"armGroups":7,"interventions":39,"overallOfficials":16,"centralContacts":16,"locations":45,"responsibleParty":136,"collaborators":16,"id":138,"slug":16,"hasResults":139,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":139,"sex":145,"minAge":146,"maxAge":16,"enrollmentInfo":147,"targetDuration":16,"studyType":150,"phases":151,"briefSummary":154,"conditions":155,"keywords":160,"overallStatus":48,"whyStopped":16,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":173},{"fullName":5,"class":6},"Recursion Pharmaceuticals Inc.","INDUSTRY",[8,14,18,21,24,27,30,33,36],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase 1a","EXPERIMENTAL","Dose Finding",[13],"Drug: REC-1245",{"label":15,"type":10,"description":16,"interventionNames":17},"Phase 1b Cohort A",null,[13],{"label":19,"type":10,"description":16,"interventionNames":20},"Phase 1b Cohort B",[13],{"label":22,"type":10,"description":16,"interventionNames":23},"Phase 1b Cohort C",[13],{"label":25,"type":10,"description":16,"interventionNames":26},"Phase 1b Cohort D",[13],{"label":28,"type":10,"description":16,"interventionNames":29},"Phase 2 Cohort 1 Dose #1",[13],{"label":31,"type":10,"description":16,"interventionNames":32},"Phase 2 Cohort 1 Dose #2",[13],{"label":34,"type":10,"description":16,"interventionNames":35},"Phase 2 Cohort 2 Dose #1",[13],{"label":37,"type":10,"description":16,"interventionNames":38},"Phase 2 Cohort 2 Dose #2",[13],[40],{"type":41,"name":42,"description":43,"armGroupLabels":44,"otherNames":16},"DRUG","REC-1245","Oral",[9,15,19,22,25,28,31,34,37],[46,65,80,91,106,122],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"City of Hope","RECRUITING","Duarte","California","91010","United States",{"type":54,"coordinates":55},"Point",[56,57],-117.97729,34.13945,{"lat":57,"lon":56},[60],{"name":61,"role":62,"phone":63,"phoneExt":16,"email":64},"Mihae Song","CONTACT","877-467-3411","misong@coh.org",{"facility":66,"status":48,"city":67,"state":68,"zip":69,"country":52,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Cleveland Clinic","Cleveland","Ohio","44195",{"type":54,"coordinates":71},[72,73],-81.69541,41.4995,{"lat":73,"lon":72},[76],{"name":77,"role":62,"phone":78,"phoneExt":16,"email":79},"Jessica Grenbenc","216-444-7923","canceranswer@ccf.org",{"facility":81,"status":82,"city":83,"state":84,"zip":85,"country":52,"cosmosGeoPoint":86,"geoPoint":90,"contacts":16},"SCRI Oncology Partners - PPDS","WITHDRAWN","Nashville","Tennessee","37203",{"type":54,"coordinates":87},[88,89],-86.78444,36.16589,{"lat":89,"lon":88},{"facility":92,"status":48,"city":93,"state":94,"zip":95,"country":52,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"START Mountain Region","West Valley City","Utah","84119",{"type":54,"coordinates":97},[98,99],-112.00105,40.69161,{"lat":99,"lon":98},[102],{"name":103,"role":62,"phone":104,"phoneExt":16,"email":105},"Marie Asay","801-907-4750","marie.asay@startresearch.com",{"facility":107,"status":48,"city":108,"state":109,"zip":110,"country":111,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"Princess Margaret Cancer Centre","Toronto","Ontario","M5G 1X6","Canada",{"type":54,"coordinates":113},[114,115],-79.39864,43.70643,{"lat":115,"lon":114},[118],{"name":119,"role":62,"phone":120,"phoneExt":16,"email":121},"Anh Nguyen","416-946-4501","anh.nguyen2@uhn.ca",{"facility":123,"status":48,"city":124,"state":16,"zip":125,"country":111,"cosmosGeoPoint":126,"geoPoint":130,"contacts":131},"McGill University Health Centre (MUHC) - The Montreal","Québec","H4A3J1",{"type":54,"coordinates":127},[128,129],-71.21454,46.81228,{"lat":129,"lon":128},[132],{"name":133,"role":62,"phone":134,"phoneExt":16,"email":135},"Phuong-nam Nguyen","5149341934","Phuong-nam.Nguyen@muhc.mcgill.ca",{"type":137,"investigatorFullName":16,"investigatorTitle":16,"investigatorAffiliation":16,"oldNameTitle":16,"oldOrganization":16},"SPONSOR","100568241",false,"NCT06678659","A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer","A Phase 1 \u002F 2, Open-Label Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer","DAHLIA","Inclusion Criteria:\n\n* Have histologically-confirmed unresectable, locally advanced, or metastatic select solid tumors or select relapsed \u002F refractory lymphoma\n* Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a given tumor type, or have been considered ineligible for standard therapy.\n* Eastern cooperative oncology group (ECOG) performance status ≤1; for adolescent participants, Lansky Performance Status Scale or Karnofsky Performance Status Scale score of ≥70.\n* Measurable disease at baseline per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 \u002F Lugano criteria and documented by computed tomography (CT) and \u002F or magnetic resonance imaging (MRI)\n\nExclusion Criteria:\n\n* Received treatment with another RBM39 degrader\n* Clinically significant gastrointestinal (GI) or GI malabsorption","ALL","12 Years",{"count":148,"type":149},170,"ESTIMATED","INTERVENTIONAL",[152,153],"PHASE1","PHASE2","This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.",[156,157,158,159],"Unresectable","Locally Advanced","Metastatic Cancers","Relapsed\u002FRefractory Lymphomas",[161,162,163,158],"RBM39","Cancer","Refractory Lymphomas","2026-05-06",{"date":166,"type":167},"2026-05-08","ACTUAL",{"date":169,"type":167},"2024-11-21",{"date":171,"type":149},"2028-10-30",{"name":5,"class":6},6]